Evidence map›Paper›PMID 34072372›Full record

ArticleLife (Basel, Switzerland)2021

Insulin-Like Growth Factor-II and Ischemic Stroke-A Prospective Observational Study.

Daniel Åberg, N David Åberg, Katarina Jood, Petra Redfors, Christian Blomstrand, Jörgen Isgaard, Christina Jern, Johan Svensson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Daniel ÅbergInstitute of Medicine, Department of Internal Medicine and Clinical Nutrition, The Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden.ORCID 0000-0003-0517-6331
N David ÅbergInstitute of Medicine, Department of Internal Medicine and Clinical Nutrition, The Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden.ORCID 0000-0002-1474-5666
Katarina JoodRegion Västra Götaland, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
Petra RedforsRegion Västra Götaland, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.
Christian BlomstrandRegion Västra Götaland, Sahlgrenska University Hospital, 413 45 Gothenburg, Sweden.ORCID 0000-0003-3503-860X
Jörgen IsgaardInstitute of Medicine, Department of Internal Medicine and Clinical Nutrition, The Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden.
Christina JernInstitute of Neuroscience and Physiology, Department of Clinical Neuroscience, The Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden.
Johan SvenssonInstitute of Medicine, Department of Internal Medicine and Clinical Nutrition, The Sahlgrenska Academy, University of Gothenburg, 405 30 Gothenburg, Sweden.
Sahlgrenska University Hospital · SEUniversity of Gothenburg · SE

Funding

Hjärt-Lungfonden 20190203Svenska Läkaresällskapet NASwedish Government ALF ALFGBG-719761Swedish Government ALF ALFGBG-720081Swedish Government ALF ALFGBG-722371Swedish Research Council 2018-02543the Göteborg Foundation for Neurological Research NAthe Rune and Ulla Amlöv, Edit Jacobson, Magnus Bergvall, Emelle, Lars Hierta, and John and Brit Wennerström foundations. NAthe Swedish Stroke Association NA
6 · The paper itself

Abstract

Insulin-like growth factor-II (IGF-II) regulates prenatal brain development, but the role in adult brain function and injury is unclear. Here, we determined whether serum levels of IGF-II (s-IGF-II) are associated with mortality and functional outcome after ischemic stroke (IS). The study population comprised ischemic stroke cases (n = 492) and controls (n = 514) from the Sahlgrenska Academy Study on Ischemic Stroke (SAHLSIS). Functional outcome was evaluated after 3 months and 2 years using the modified Rankin Scale (mRS), and additionally, survival was followed at a minimum of 7 years or until death. S-IGF-II levels were higher in IS cases both in the acute phase and at 3-month follow-up compared to controls (

Indexed as

functional outcomeinsulin-like growth factor-IIischemic strokemodified Rankin ScalemortalityNational Institutes of Health Stroke Scale (NIHSS)

Identifiers

PMID34072372
PMCPMC8230196
OpenAlexW3164465756

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.